| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Studies |
Division of Endocrinology, Developmental Endocrinology Unit and Hormone and Molecular Genetics Laboratory (M.C.B.V.F., A.C.L., J.A.M.M., V.S.L., E.T.F., B.B.M., S.M.F.V.), Department of Pathology (F.M.C., M.C.N.Z.), Hospital das Clínicas, São Paulo University School of Medicine, São Paulo; Unit of Endocrinology, Hospital Universitário Professor Edgard Santos, Bahia University School of Medicine (L.M.B.A.), Salvador, Brazil
Address all correspondence and requests for reprints to: Dr. Sandra M. F. Villares, Hospital das Clínicas, Endocrinologia, Caixa Postal 3671, CEP 01060970, Sao Paulo, Brazil. E-mail: smvillar{at}usp.br
Activating mutations of the G protein genes have been associated with
the development of several endocrine neoplasms. Such activating
mutations, gip2, affecting the
-subunit of the
G
i2 protein were previously described by a single group
in 30% of ovarian sex cord stromal tumors. Other activating mutations
of the
-subunit of the Gs (gsp) have been
identified in GH-secreting and nonfunctioning pituitary tumors,
autonomous thyroid adenomas, and all affected McCune-Albright tissues,
but not in sex cord stromal tumors. In the present study, we
investigated the presence of gip2 and gsp
mutations in 14 human sex cord stromal tumors. Six Leydig cell tumors
(4 ovaries and 2 testes), 2 thecomas, 2 granulosa cell tumors, 3
androblastomas, and 1 gonadoblastoma (sex cord and germ cell) were
included in this study. Genomic DNA was obtained from either
fresh-frozen tumor tissues or paraffin-embedded sections and in some
cases from blood samples. Using PCR, denaturing gradient gel
electrophoresis, and direct sequencing, we detected 4 tumors (66.6%)
with the gsp mutation (R201C) in our series of ovarian
and testicular Leydig cell tumors. In contrast, no gip2
mutations were found in any of the sex cord stromal tumors studied. In
conclusion, our findings suggest that the putative oncogene
gsp may play a significant role in the molecular
mechanism of these tumors.
This article has been cited by other articles:
![]() |
M.-N. Lague, M. Paquet, H.-Y. Fan, M. J. Kaartinen, S. Chu, S. P. Jamin, R. R. Behringer, P. J. Fuller, A. Mitchell, M. Dore, et al. Synergistic effects of Pten loss and WNT/CTNNB1 signaling pathway activation in ovarian granulosa cell tumor development and progression Carcinogenesis, November 1, 2008; 29(11): 2062 - 2072. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Hahn, U. H Frey, W. Siffert, S. Tan, K. Mann, and O. E Janssen The CC genotype of the GNAS T393C polymorphism is associated with obesity and insulin resistance in women with polycystic ovary syndrome. Eur. J. Endocrinol., November 1, 2006; 155(5): 763 - 770. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. P. Prevost, M. O. Lonchampt, S. Holbeck, S. Attoub, D. Zaharevitz, M. Alley, J. Wright, M. C. Brezak, H. Coulomb, A. Savola, et al. Anticancer Activity of BIM-46174, a New Inhibitor of the Heterotrimeric G{alpha}/G{beta}{gamma} Protein Complex. Cancer Res., September 15, 2006; 66(18): 9227 - 9234. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. G. Carvajal-Carmona, N. A. Alam, P. J. Pollard, A. M. Jones, E. Barclay, N. Wortham, M. Pignatelli, A. Freeman, S. Pomplun, I. Ellis, et al. Adult Leydig Cell Tumors of the Testis Caused by Germline Fumarate Hydratase Mutations J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 3071 - 3075. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Kalfa, A. Ecochard, C. Patte, P. Duvillard, F. Audran, C. Pienkowski, E. Thibaud, R. Brauner, C. Lecointre, D. Plantaz, et al. Activating Mutations of the Stimulatory G Protein in Juvenile Ovarian Granulosa Cell Tumors: A New Prognostic Factor? J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1842 - 1847. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Piaditis, A. Angellou, G. Kontogeorgos, N. Mazarakis, T. Kounadi, G. Kaltsas, K. Vamvakidis, R. V. Lloyd, E. Horvath, and K. Kovacs Ectopic Bioactive Luteinizing Hormone Secretion by a Pancreatic Endocrine Tumor, Manifested as Luteinized Granulosa-Thecal Cell Tumor of the Ovaries J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2097 - 2103. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Basciani, M. Brama, S. Mariani, G. De Luca, M. Arizzi, L. Vesci, C. Pisano, S. Dolci, G. Spera, and L. Gnessi Imatinib Mesylate Inhibits Leydig Cell Tumor Growth: Evidence for In vitro and In vivo Activity Cancer Res., March 1, 2005; 65(5): 1897 - 1903. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Lania, G. Mantovani, and A. Spada Genetics of Pituitary Tumors: Focus on G-Protein Mutations Experimental Biology and Medicine, October 1, 2003; 228(9): 1004 - 1017. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. T. Collins, N. J. Sarlis, M. J. Merino, J. Monroe, S. E. Crawford, J. A. Krakoff, L. C. Guthrie, S. Bonat, P. G. Robey, and A. Shenker Thyroid Carcinoma in the McCune-Albright Syndrome: Contributory Role of Activating Gs{alpha} Mutations J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4413 - 4417. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. B. V. Fragoso, S. Domenice, A. C. Latronico, R. M. Martin, M. A. A. Pereira, M. C. N. Zerbini, A. M. Lucon, and B. B. Mendonca Cushing's Syndrome Secondary to Adrenocorticotropin-Independent Macronodular Adrenocortical Hyperplasia due to Activating Mutations of GNAS1 Gene J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 2147 - 2151. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Richter-Unruh, H. T. Wessels, U. Menken, M. Bergmann, K. Schmittmann-Ohters, J. Schaper, S. Tappeser, and B. P. Hauffa Male LH-Independent Sexual Precocity in a 3.5-Year-Old Boy Caused by a Somatic Activating Mutation of the LH Receptor in a Leydig Cell Tumor J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 1052 - 1056. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. Choong, P. J. Fuller, S. Chu, Y. Jeske, F. Bowling, R. Brown, P. Borzi, N. D. Balazs, R. Suppiah, A. M. Cotterill, et al. Sertoli-Leydig Cell Tumor of the Ovary, a Rare Cause of Precocious Puberty in a 12-Month-Old Infant J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 49 - 56. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. H. Jorge, S. K. Agarwal, V. S. Lando, R. Salvatori, R. R. Barbero, N. Abelin, M. A. Levine, S. J. Marx, and S. P. A. Toledo Study of the Multiple Endocrine Neoplasia Type 1, Growth Hormone-Releasing Hormone Receptor, Gs{{alpha}}, and Gi2{{alpha}} Genes in Isolated Familial Acromegaly J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 542 - 544. [Abstract] [Full Text] |
||||
![]() |
A. P. N. Themmen and I. T. Huhtaniemi Mutations of Gonadotropins and Gonadotropin Receptors: Elucidating the Physiology and Pathophysiology of Pituitary-Gonadal Function Endocr. Rev., October 1, 2000; 21(5): 551 - 583. [Abstract] [Full Text] |
||||
![]() |
G. Liu, L. Duranteau, J.-C. Carel, J. Monroe, D. A. Doyle, and A. Shenker Leydig-Cell Tumors Caused by an Activating Mutation of the Gene Encoding the Luteinizing Hormone Receptor N. Engl. J. Med., December 2, 1999; 341(23): 1731 - 1736. [Full Text] [PDF] |
||||
![]() |
H. G. Brunner and B. J. Otten Precocious Puberty in Boys N. Engl. J. Med., December 2, 1999; 341(23): 1763 - 1765. [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |